Study to test if CBD reduces Parkinson's psychosis

L-R: Nishi Singh, Kimberley Gillman and Dr Anita Goff have recruited local patients in Somerset for the trial

Researchers in Somerset are joining others across the UK to investigate whether cannabidol, or CBD, can treat psychotic symptoms in Parkinson's patients.

Studies have shown that CBD may reduce psychosis, although it had not yet been tested with Parkinson's patients.

Somerset NHS Foundation Trust said around three in five people with the condition experienced symptoms including hallucinations or delusions.

The NHS said the trial could offer a safer option as current treatments for the condition were not effective, safe, or convenient for regular use.

CBD is a chemical which is found in the cannabis plant. In recent years it has become popular as a health supplement.

120 patients from across the UK will be recruited for the study.

Nishi Singh, a research nurse at Somerset NHS Foundation Trust, said: "I think it's a really exciting study for our trust to be involved in and it could make a huge difference for patients with Parkinson's who're experiencing psychosis.

"We know that not all patients with Parkinson's have symptoms of psychosis, delusions or hallucinations, but for those who do, it'll be good to understand whether CBD can have a therapeutic effect in reducing those symptoms."

Psychosis 'debilitating'

Dr Sarah Cleaver, principal investigator for the study, added: "It's really exciting to be part of a national study looking to improve the quality of life of patients suffering with psychosis alongside their Parkinsons.

"Our current options for treatment are limited and psychosis can be so debilitating."

Though the main trial is in London, the Somerset trust is the only one in the south west taking part, so it will host patients from Devon and Cornwall too.

Participants will be given capsules containing either CBD or a placebo for 12 weeks, and will be monitored throughout.